Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px
Financing › Details

Affimed–SEVERAL: investment, 202204 public offering $90m+$13.5m with 22.5m+3.375m common shares at $4/share PRICED

 

Period Period 2022-04-12 ï¿½ 2022-04-18
Region Region United States (USA)
  Predecessor Affimed–SEVERAL: investment, 202101 public offering $100m+$15m with 16.7m+2.5m common shares at $6/share
Organisations Money taker Affimed N.V. (Nasdaq: AFMD)
  Group Affimed (Group)
  Money source SEVERAL
Products Product ROCK® (Redirected Optimized Cell Killing) platform
  Product 2 investment banking
     

Affimed N.V.. (4/13/22). "Press Release: Affimed Announces Pricing of Upsized $90 Million Public Offering of Common Shares". Heidelberg.

Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the pricing of its previously announced public offering of 22,500,000 of its common shares at a public offering price of $4.00 per common share. In addition, Affimed has granted the underwriters a 30-day over-allotment option to purchase up to 3,375,000 common shares at the public offering price less underwriting discounts. After deducting the underwriting discounts, the net proceeds of the public offering are expected to be $84.6 million. The offering is expected to close on or about April 18, 2022, subject to customary closing conditions.

Jefferies LLC, SVB Leerink, Truist Securities, Inc. and Wells Fargo Securities, LLC are acting as joint book-running managers and Berenberg Capital Markets LLC is acting as a co-manager of the offering. A shelf registration statement relating to these securities filed with the Securities and Exchange Commission (the “SEC”) was declared effective by the SEC on April 6, 2022. The offering will be made only by means of a prospectus and prospectus supplement. A preliminary prospectus supplement and accompanying prospectus related to the offering have been filed with the SEC and are available at the SEC’s website located at www.sec.gov. A final prospectus supplement and accompanying prospectus will be filed with the SEC. Copies of the preliminary prospectus supplement and accompanying prospectus related to the offering may be obtained by contacting Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877) 821-7388 or by email at Prospectus_Department@Jefferies.com, SVB Securities LLC, Attn: Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109, by telephone at 1-800-808-7525, ext. 6105, or by email at syndicate@svbleerink.com, Truist Securities, Inc., Attention: Prospectus Department, 3333 Peachtree Road, NE, 11th Floor, Atlanta, Georgia 30326, by telephone at (800) 685-4786, or by email at TruistSecurities.prospectus@Truist.com, or Wells Fargo Securities, LLC, Attention: Equity Syndicate Department, 500 West 33rd Street, New York, New York 10001, by telephone at (833) 690-2713, or by email at cmclientsupport@wellsfargo.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.


About Affimed N.V.

Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The Company’s proprietary ROCK® platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK® platform predictably generates customized innate cell engager (ICE®) molecules, which use patients’ immune cells to destroy tumor cells. This innovative approach enabled Affimed to become the first company with a clinical-stage ICE®. Headquartered in Heidelberg, Germany, with offices in New York, NY, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by a bold vision to stop cancer from ever derailing patients’ lives.


Forward-looking Statements

This press release contains statements that constitute “forward-looking statements,” including with respect to the proposed offering of common shares and the anticipated use of the net proceeds. No assurance can be given that the offering discussed above will be completed on the terms described, or at all, or that the net proceeds of the offering will be used as indicated. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the company, including those set forth in the Risk Factors section of the company’s registration statement and preliminary prospectus for the company’s offering filed with the Securities and Exchange Commission (“SEC”). Copies are available on the SEC’s website, www.sec.gov. Given these risks, uncertainties, and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.


Affimed Investor and Media Contact:

Alexander Fudukidis
Director, Head of Investor Relations
E-Mail: a.fudukidis@affimed.com, IR@affimed.com
Tel.: +1 (917) 436-8102

   
Record changed: 2022-04-13

Advertisement

Picture [iito] Männer Ballett 650x100px

More documents for Affimed (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px




» top